Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275480 | 0.86 | GAA (0.37) | ITGB3ITGA2BL3MBTL1 | |
| SCHEMBL7634160 | 0.84 | ALDH1A1 (0.35) | ITGB3ITGA2BTDP1 | |
| SCHEMBL7634164 | 0.84 | ALDH1A1 (0.35) | ITGB3ITGA2BTDP1 | |
| SCHEMBL7283424 | 0.81 | TDP1 (0.36) | ITGB3ITGA2BL3MBTL1TDP1HCRTR1 | |
| SCHEMBL6345797 | 0.76 | PLA2G10 (0.36) | L3MBTL1TDP1HCRTR1PLA2G10PLA2G5 | |
| SCHEMBL7285264 | 0.72 | ITGB3 (0.53) | ITGB3ITGA2B | |
| SCHEMBL23392378 | 0.72 | IRAK4 (0.31) | — | |
| SCHEMBL7285166 | 0.72 | ALDH1A1 (0.36) | — | |
| SCHEMBL7276650 | 0.72 | ALDH1A1 (0.36) | — | |
| SCHEMBL7281904 | 0.72 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334684-B1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-9079905-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-2334684-A1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010026214-A1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| EP-0528369-B1 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-11-24 | — | — | EP | disclosed |
| EP-0567966-B1 | Cyclic imino derivatives, medicaments containing these compounds and processes for the production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 1998-09-02 | — | — | EP | disclosed |
| EP-0483667-B1 | Cyclic imino derivatives, process for their preparation and drugs containing them | THOMAE GMBH DR K (DE) | 1998-02-04 | — | — | EP | disclosed |
| US-5591769-A | PYRROLIDINE DERIVATIVES; ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5576444-A | ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1996-11-19 | — | — | US | disclosed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5455348-A | Anticoagulants | Thomae, Karl (DE) | 1995-10-03 | — | — | US | disclosed |
| EP-0567966-A1 | Cyclic imino derivatives, medicaments containing these compounds and processes for the production thereof | Dr. Karl Thomae GmbH (DE) | 1993-11-03 | — | — | EP | disclosed |
| EP-0528369-A2 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-02-24 | — | — | EP | disclosed |
| EP-0483667-A2 | Cyclic imino derivatives, process for their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CNR1, CNR2, CHRM5 | ITGB3 4749/4885ITGA2B 4861/4885L3MBTL1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.